VISIT NUTRACEUTICALS WORLD at Booth 4872 TEST

Catalent Appoints GM of Philadelphia Clinical Supply Facility

08.13.21

Harold A. Jenkins III brings more than 28 years of leadership experience.

Catalent, a global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, has appointed Harold A. Jenkins III, as General Manager of its recently expanded Philadelphia facility, the company’s North American center of excellence for clinical supply packaging.
 
Mr. Jenkins brings more than 28 years of leadership experience, and joins the company from GE Healthcare, where he worked for 18 years, holding positions including X-Ray Service Operations Director for the Americas, and Director of Service for the Connecticut and Atlanta regions. Prior to GE Healthcare, Mr. Jenkins worked at Fujitsu Network Communications and served for more than seven years in the United States Army.
 
“Our Philadelphia site is the largest clinical supply facility in our network, and the services it offers have adapted over time to meet the needs of ever-growing complexity of trials, and changes to sponsors’ needs, including to ensure the successful supply of trials during the pandemic,” commented Ricci Whitlow, President, Clinical Supply Services at Catalent. “I am delighted to welcome Harold to head up the site, and his experience and leadership will be invaluable to capitalize on the changes and challenges of the future.” 
 
In April 2021, Catalent expanded capabilities at the 200,000 sq.-ft. Philadelphia facility to include cryogenic handling and storage capacity to support sponsors developing cell and gene therapies. The facility houses an on-site pharmacy to support FlexDirect direct-to-patient service for clinical trials, and offers customers access to Catalent’s FastChain demand-led supply services, primary and secondary packaging capabilities, as well as a range of temperature options for storage and distribution, and clinical returns and destruction services.